Healthcare Industry News: Elaprase
News Release - October 26, 2006
DAYTRANA(TM) (methylphenidate transdermal system) Provides Individualized Symptom ManagementShorter Wear Time Provides Shorter Duration of Effect, Offering Individualized ADHD Symptom Management
SAN DIEGO, Oct. 26 (HSMN NewsFeed) -- Shire plc (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ) announced that its Attention Deficit Hyperactivity Disorder (ADHD) patch, DAYTRANA(TM) (methylphenidate transdermal system), has significant efficacy in reducing the symptoms of ADHD in children aged 6 to 12 years, even when the ADHD patch is taken off earlier than the recommended nine hours. The ability to remove the patch earlier than the recommended nine-hour wear time allows physicians the opportunity to manage the potential for late-day side effects, such as lack of appetite or difficulty sleeping. These phase IIIb clinical trial results were reported today at a major scientific and educational meeting of child and adolescent psychiatrists in San Diego, Calif.
Shire's DAYTRANA is the first and only patch medication approved by the U.S. Food and Drug Administration (FDA) to treat the symptoms of pediatric ADHD. DAYTRANA is available in four dosage strengths -- 10 mg, 15 mg, 20 mg and 30 mg -- all designed for once-daily use. When worn for the recommended nine hours, efficacy has been demonstrated from the first time point measured (two hours) through the 12-hour time point.
Noven Pharmaceuticals, Inc. developed DAYTRANA, which combines the active ingredient, methylphenidate, with Noven's patented DOT Matrix(TM) transdermal technology. This transdermal delivery system was designed to provide continuous medication release throughout the day. The patch is designed to stay on during the normal daily activities of a child such as swimming, exercising or bathing.
Significant Symptom Control With DAYTRANA When Worn for Four or Six Hours
In this study, investigators researched the duration of symptom control of DAYTRANA when the patch was worn for four and six hours compared to a placebo patch. Study results were based on the children's scores on the primary study measure, the standard Swanson, Kotkin, Agler, M-Flynn, and Pelham Rating Scale deportment (SKAMP-D), a standardized, validated classroom assessment tool used for evaluating the behavioral symptoms of ADHD. Higher SKAMP-D ratings reflect greater impairment.
Improvement in the SKAMP-D scores for both the four- and six-hour wear time groups was seen at the first time point measured (2 hours), compared to placebo. When DAYTRANA was removed after four and six hours of wear time, mean SKAMP-D scores began to return toward baseline within two hours of patch removal. A similar effect was observed by the Permanent Product Measure of Performance (PERMP) test of the number of math problems attempted and completed correctly.
In the three-way cross-over study, 117 children aged 6 to 12 years diagnosed with ADHD were started on the 10-mg patch, and the dosage was increased during a five-week period until the optimal DAYTRANA dose was reached. The laboratory classroom study period covered three weeks including one classroom laboratory day per week, with the patients wearing the patch for nine hours for days in between the classroom laboratory days. Then, on the three laboratory classroom days only, the researchers randomized the children to treatment with a placebo patch or a DAYTRANA patch and either four- or six-hour wear times, but neither the investigators nor the children knew which treatment was received until study end. The results reported in this poster were based on analyses of the intent-to-treat population.
Study Safety Information
DAYTRANA was generally well-tolerated during this study. Adverse events typically were mild to moderate and were consistent with known effects of methylphenidate. The most common adverse events seen in the trial included: decreased appetite, headache, insomnia and upper abdominal pain.
The study was supported by funding from Shire.
Important Safety Information
Tell your doctor about any heart conditions, including structural abnormalities, your child or a family member may have. Inform your doctor immediately if the child develops symptoms that suggest heart problems, such as chest pain or fainting.
Daytrana should not be used if the child has: significant anxiety, tension, or agitation; allergies to methylphenidate or other ingredients of Daytrana; glaucoma; discontinued in the last 14 days or is taking a monoamine oxidase inhibitor (MAOI); tics, or family history or diagnosis of Tourette's syndrome.
Tell your doctor before using Daytrana if the child: is being treated for or has symptoms of depression (e.g. sadness, worthlessness, or hopelessness) or bipolar disorder; has family history of tics; has abnormal thoughts or visions, hears abnormal sounds, or has been diagnosed with psychosis; has had seizures or abnormal EEGs; has or has had high blood pressure; exhibits aggressive behavior or hostility. Tell your doctor immediately if the child develops any of these conditions/symptoms while using Daytrana.
Daytrana was generally well tolerated in clinical studies. The most common side effects reported with Daytrana were decreased appetite, sleeplessness, sadness/crying, twitching, weight loss, nausea, vomiting, tics, and affect lability (mood swings). Aggression, new abnormal thoughts/behaviors, mania, and growth suppression have been associated with use of drugs of this type. Tell your doctor if the child has blurred vision while using Daytrana.
Abuse of Daytrana can lead to dependence.
Patients converting from another formulation of methylphenidate should start on the 10-mg DAYTRANA patch. Daytrana should be applied daily to clean, dry skin, which is free of any cuts or irritation. Skin irritation or allergic skin rash may occur.
For Full Prescribing Information on Daytrana, please visit http://www.Daytrana.com or call Shire Medical Affairs at 1-800-828-2088, option 1.
Approximately 7.8 percent of all school-age children, or about 4.4 million U.S. children aged 4 to 17 years, have been diagnosed with ADHD at some point in their lives, according to the U.S. Centers for Disease Control and Prevention (CDC). ADHD is one of the most common psychiatric disorders in children and adolescents. ADHD is a neurobiological psychiatric disorder that manifests as a persistent pattern of inattention and/or hyperactivity-impulsivity that is more frequent and severe than is typically observed in individuals at a comparable level of development. To be properly diagnosed with ADHD, a child needs to demonstrate at least six of nine symptoms of inattention; at least six of nine symptoms of hyperactivity/impulsivity; the onset of such symptoms before age 7 years; that some impairment from the symptoms is present in two or more settings (e.g., at school and home); that the symptoms continue for at least six months; and that there is clinically significant impairment in social, academic or occupational functioning.
Although there is no "cure" for ADHD, there are accepted treatments that specifically target its symptoms. The most common standard treatments include educational approaches, psychological or behavioral modification, and medication.
Notes to editors
Shire's strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.
Shire's focused strategy is to develop and market products for specialty physicians. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.
For further information on Shire, please visit the Company's website: http://www.shire.com.
"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research, product development, manufacturing and commercialization; the impact of competitive products, including, but not limited to the impact of those on Shire's Attention Deficit and Hyperactivity Disorder (ADHD) franchise; patents, including but not limited to, legal challenges relating to Shire's ADHD franchise; government regulation and approval, including but not limited to the expected product approval dates of SPD503 (guanfacine extended release) (ADHD), SPD465 (extended release of mixed amphetamine salts) (ADHD), MESAVANCE (mesalamine) with MMX technology (SPD 476) (ulcerative colitis), Elaprase (idursulfase) (Hunter Syndrome) and NRP104 (lisdexamfetamine dimesylate) (ADHD), including its scheduling classification by the Drug Enforcement Administration in the United States; Shire's ability to secure new products for commercialization and/or development; and other risks and uncertainties detailed from time to time in Shire's and its predecessor registrant Shire Pharmaceuticals Group plc's filings with the Securities and Exchange Commission, particularly Shire plc's Annual Report on Form 10-K for the year ended December 31, 2005.
Daytrana(TM) is a trademark of Shire Pharmaceuticals Ireland Limited.
Source: Shire plc
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.